Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...
Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
Hims & Hers to sell Lilly’s Zepbound
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Lilly, Novo expand DTC reach of obesity meds after compound win
Eli Lilly and Novo Nordisk have scored big wins from the FDA in recent months, as the agency cracks down on copycat versions ...
Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list
Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter.